A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Migraine

Interventions

DRUG: Atogepant
DRUG: Placebo for Atogepant

Sponsor

AbbVie